Search

Displaying results 4421 - 4430 of 8412 in total
  1. Drug

    (1H-indol-3-yl)-(2-mercapto-ethoxyimino)-acetic acid

    go.drugbank.com/drugs/DB03455
    Experimental

    These are compounds containing an acetic acid (or a derivative) linked to the C3 carbon atom of an indole. (1H-indol-3-yl)-(2-mercapto-ethoxyimino)-acetic acid is known to target interleukin-2.

  2. Drug

    Gambir

    go.drugbank.com/drugs/DB14298
    Investigational

    It is not an approved drug.

  3. Drug

    Pomegranate

    go.drugbank.com/drugs/DB14317
    Investigational

    It is not an approved drug.

  4. Drug

    IBIO-100

    go.drugbank.com/drugs/DB18233
    Experimental

    IBIO-100 is a high molecular weight multimer of E3-Fc, an endostatin C-terminus and IgG1-Fc fusion protein.

  5. Drug

    VOR33

    go.drugbank.com/drugs/DB18624
    Investigational

    VOR33 is an allogeneic CRISPR/Cas9 genome-edited hematopoietic stem and progenitor cell (HSPC) therapy product lacking the CD33 protein.

  6. Drug

    Arbekacin

    go.drugbank.com/drugs/DB06696
    Investigational

    An semisynthetic aminoglycoside antibiotic. Often used for treatment of multi-resistant bacterial infection such as methicillin-resistant _Staphylococcus aureus_ (MRSA).

  7. Drug

    Borage oil

    go.drugbank.com/drugs/DB11238
    Approved

    Borage oil is used as an herbal treatment of skin disorders including eczema, seborrheic dermatitis, and neurodermatitis as well as other inflammatory, cardiovascular and endocrine disorders, although

  8. Drug

    DA-6886

    go.drugbank.com/drugs/DB12853
    Investigational

    DA-6886 has been used in trials studying the treatment of Irritable Bowel Syndrome.

  9. Drug

    Methyl-D9-choline

    go.drugbank.com/drugs/DB12628
    Investigational

    Methyl-D9-choline is under investigation in clinical trial NCT01807910 (ER Stress in NAFLD).

  10. Drug

    Eflapegrastim

    go.drugbank.com/drugs/DB15001
    ApprovedInvestigational

    [A252320] It typically develops during the first cycle of chemotherapy and is associated with an increased risk of morbidity and mortality. … as the co-occurrence of fever (temperature > 38 ◦C) and severe neutropenia (ANC < 500 cells/mm<sup>3</sup>), is a potential side effect of myelosuppressive chemotherapy in which the patient develops an